$ELTX
Elicio Therapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000160148522000070 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.745M $3.315M
YoY Change -10.96% -15.65%
% of Gross Profit
Research & Development $160.0K $2.938M
YoY Change -97.6% -77.89%
% of Gross Profit
Depreciation & Amortization $31.00K $84.00K
YoY Change -3.13% 265.22%
% of Gross Profit
Operating Expenses $3.905M $2.938M
YoY Change -64.09% -77.89%
Operating Profit -$9.050M
YoY Change -42.57%
Interest Expense $606.0K $53.00K
YoY Change -3887.5% -171.62%
% of Operating Profit
Other Income/Expense, Net $5.000K $62.00K
YoY Change -98.16% 14.81%
Pretax Income -$6.440M -$8.988M
YoY Change -143.25% -42.77%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$6.440M -$8.988M
YoY Change -143.25% -42.77%
Net Earnings / Revenue
Basic Earnings Per Share -$0.30
Diluted Earnings Per Share -$0.21 -$0.30
COMMON SHARES
Basic Shares Outstanding 30.11M shares 30.11M shares
Diluted Shares Outstanding 30.11M shares

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $50.49M $55.14M
YoY Change -43.12% -46.33%
Cash & Equivalents $50.50M $55.10M
Short-Term Investments
Other Short-Term Assets $246.0K $326.0K
YoY Change -50.6% -40.62%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $51.43M $56.68M
YoY Change -43.64% -45.71%
LONG-TERM ASSETS
Property, Plant & Equipment $273.0K $304.0K
YoY Change -39.47% -36.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $874.0K $874.0K
YoY Change 20.89% 1.39%
Other Assets $61.00K $75.00K
YoY Change -42.45% 127.27%
Total Long-Term Assets $1.360M $4.636M
YoY Change -74.17% -16.42%
TOTAL ASSETS
Total Short-Term Assets $51.43M $56.68M
Total Long-Term Assets $1.360M $4.636M
Total Assets $52.79M $61.32M
YoY Change -45.3% -44.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.720M $2.218M
YoY Change -42.25% -71.12%
Accrued Expenses $2.569M $4.908M
YoY Change -20.19% -8.24%
Deferred Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $67.00K $64.00K
YoY Change 15.52%
Total Short-Term Liabilities $6.369M $8.182M
YoY Change -43.62% -54.41%
LONG-TERM LIABILITIES
Long-Term Debt $168.0K $186.0K
YoY Change
Other Long-Term Liabilities $2.481M $2.738M
YoY Change -90.04%
Total Long-Term Liabilities $2.649M $2.924M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.369M $8.182M
Total Long-Term Liabilities $2.649M $2.924M
Total Liabilities $9.018M $11.11M
YoY Change -39.9% -75.55%
SHAREHOLDERS EQUITY
Retained Earnings -$253.9M -$247.5M
YoY Change 18.02% 7.61%
Common Stock $301.0K $301.0K
YoY Change 0.33% -0.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $43.77M $50.21M
YoY Change
Total Liabilities & Shareholders Equity $52.79M $61.32M
YoY Change -45.3% -44.23%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$6.440M -$8.988M
YoY Change -143.25% -42.77%
Depreciation, Depletion And Amortization $31.00K $84.00K
YoY Change -3.13% 265.22%
Cash From Operating Activities -$4.426M -$8.406M
YoY Change -69.18% -44.69%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -15.00K -17.00K
YoY Change -103.71% -102.43%
NET CHANGE
Cash From Operating Activities -4.426M -8.406M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities -15.00K -17.00K
Net Change In Cash -4.441M -8.423M
YoY Change -68.26% -42.15%
FREE CASH FLOW
Cash From Operating Activities -$4.426M -$8.406M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$4.426M -$8.406M
YoY Change -69.11% -44.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001601485
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39990
dei Entity Registrant Name
EntityRegistrantName
ANGION BIOMEDICA CORP
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
11-3430072
dei Entity Address Address Line1
EntityAddressAddressLine1
51 Charles Lindbergh Boulevard
dei Entity Address City Or Town
EntityAddressCityOrTown
Uniondale
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
11553
dei City Area Code
CityAreaCode
415
dei Local Phone Number
LocalPhoneNumber
655-4899
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01
dei Trading Symbol
TradingSymbol
ANGN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30113703 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55143000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88756000 usd
CY2022Q3 us-gaap Grants Receivable Current
GrantsReceivableCurrent
0 usd
CY2021Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
806000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1537000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1685000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
56680000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
91247000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
304000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
451000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3383000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3986000 usd
CY2022Q3 us-gaap Investments
Investments
874000 usd
CY2021Q4 us-gaap Investments
Investments
723000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
75000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
106000 usd
CY2022Q3 us-gaap Assets
Assets
61316000 usd
CY2021Q4 us-gaap Assets
Assets
96513000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2218000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4710000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4908000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3219000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
968000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
894000 usd
CY2022Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
64000 usd
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
58000 usd
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0 usd
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2301000 usd
CY2022Q3 angn Warrant Liability Current
WarrantLiabilityCurrent
24000 usd
CY2021Q4 angn Warrant Liability Current
WarrantLiabilityCurrent
114000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8182000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11296000 usd
CY2022Q3 us-gaap Revenues
Revenues
0 usd
CY2021Q3 us-gaap Revenues
Revenues
1460000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2738000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3475000 usd
CY2022Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
186000 usd
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
235000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
11106000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
15006000 usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30113582 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30113582 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29959060 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29959060 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
301000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
300000 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
297109000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
296445000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
302000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-103000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-247502000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-215135000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
50210000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
81507000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
61316000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
96513000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1460000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2301000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2371000 usd
us-gaap Revenues
Revenues
2301000 usd
us-gaap Revenues
Revenues
2371000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2938000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13288000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17940000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42030000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3315000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3930000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10892000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14282000 usd
CY2022Q3 us-gaap Restructuring Charges
RestructuringCharges
2797000 usd
CY2021Q3 us-gaap Restructuring Charges
RestructuringCharges
0 usd
us-gaap Restructuring Charges
RestructuringCharges
6039000 usd
us-gaap Restructuring Charges
RestructuringCharges
0 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
9050000 usd
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
17218000 usd
us-gaap Costs And Expenses
CostsAndExpenses
34871000 usd
us-gaap Costs And Expenses
CostsAndExpenses
56312000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9050000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15758000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-32570000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-53941000 usd
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-9000 usd
CY2021Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-128000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-90000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3191000 usd
CY2022Q3 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
0 usd
CY2021Q3 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
0 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
0 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-7469000 usd
CY2022Q3 angn Financial Instruments Subject To Mandatory Redemption By Settlement Terms Change In Fair Value Gain Loss
FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss
0 usd
CY2021Q3 angn Financial Instruments Subject To Mandatory Redemption By Settlement Terms Change In Fair Value Gain Loss
FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss
0 usd
angn Financial Instruments Subject To Mandatory Redemption By Settlement Terms Change In Fair Value Gain Loss
FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss
0 usd
angn Financial Instruments Subject To Mandatory Redemption By Settlement Terms Change In Fair Value Gain Loss
FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss
-3592000 usd
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
905000 usd
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-215000 usd
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-204000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-441000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-279000 usd
CY2022Q3 us-gaap Income Loss From Equity Method Investments Net Of Dividends Or Distributions
IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
9000 usd
CY2021Q3 us-gaap Income Loss From Equity Method Investments Net Of Dividends Or Distributions
IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
20000 usd
us-gaap Income Loss From Equity Method Investments Net Of Dividends Or Distributions
IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
151000 usd
us-gaap Income Loss From Equity Method Investments Net Of Dividends Or Distributions
IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
40000 usd
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
259000 usd
CY2021Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
110000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
403000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1936000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
62000 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
54000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
203000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15522000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8988000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-15704000 usd
us-gaap Net Income Loss
NetIncomeLoss
-32367000 usd
us-gaap Net Income Loss
NetIncomeLoss
-69463000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
204000 usd
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
146000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
405000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
260000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8784000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15558000 usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27671310 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27671310 shares
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31962000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-69203000 usd
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.51
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30113407 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30113407 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29829577 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29829577 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30016079 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30016079 shares
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-96000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
81507000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
31000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-14240000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
67202000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1399000 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
297000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9139000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
59760000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-3000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-763000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
204000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8988000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
50210000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-90449000 usd
CY2021Q1 angn Stock Issued During Period Value Conversion Of Convertible Preferred Stock
StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock
35754000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
13000 usd
CY2021Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1145000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5117000 usd
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
46000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-36687000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
92443000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Stock Split
AdjustmentsToAdditionalPaidInCapitalStockSplit
10000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
79000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
6000 usd
CY2021Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
1219000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2718000 usd
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
68000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-17072000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
77189000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
77189000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
786000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
2000 usd
CY2021Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
94000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2184000 usd
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
146000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-15704000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
64514000 usd
us-gaap Net Income Loss
NetIncomeLoss
-32367000 usd
us-gaap Net Income Loss
NetIncomeLoss
-69463000 usd
us-gaap Depreciation
Depreciation
147000 usd
us-gaap Depreciation
Depreciation
59000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
603000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
519000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1884000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
667000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
10019000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
905000 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
0 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-7469000 usd
angn Financial Instruments Subject To Mandatory Redemption By Settlement Terms Change In Fair Value Gain Loss
FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss
0 usd
angn Financial Instruments Subject To Mandatory Redemption By Settlement Terms Change In Fair Value Gain Loss
FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss
-3592000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-90000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3191000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
151000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
76000 usd
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
0 usd
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
36000 usd
angn Increase Decrease In Grant Receivables
IncreaseDecreaseInGrantReceivables
-806000 usd
angn Increase Decrease In Grant Receivables
IncreaseDecreaseInGrantReceivables
0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-194000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4050000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-31000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
33000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2529000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2072000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1689000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2182000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-663000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-506000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2301000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2371000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33964000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38281000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
346000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-346000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
110560000 usd
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
3073000 usd
angn Payments For Forward Stock Split Fractional Shares
PaymentsForForwardStockSplitFractionalShares
0 usd
angn Payments For Forward Stock Split Fractional Shares
PaymentsForForwardStockSplitFractionalShares
10000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2458000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
0 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
21000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
43000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
861000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
866000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-45000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
106767000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
396000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-11000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-33613000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
68129000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88756000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34607000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55143000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
102736000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
624000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
32000 usd
CY2021Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
16.00
CY2021Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
16.00
CY2021Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0 usd
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55100000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-247500000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 operating_segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to the useful lives of long-lived assets, the measurement of stock-based compensation, accruals for research and development activities, income taxes and revenue recognition. The Company bases its estimates on historical experience and on other relevant assumptions that are reasonable under the circumstances. Actual results could materially differ from those estimates.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents are financial instruments potentially subject to concentrations of credit risk. The Company's cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash equivalents in securities and money market funds with original maturities less than three months.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no financial instruments with off-balance sheet risk of loss.</span></div>
CY2022Q3 angn Number Of Performance Obligations
NumberOfPerformanceObligations
1 performanceobligation
CY2022Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y10M24D
CY2021Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P6Y8M12D
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
968000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
968000 usd
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
664000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
517000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
304000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
451000 usd
CY2022Q3 us-gaap Prepaid Taxes
PrepaidTaxes
7000 usd
CY2021Q4 us-gaap Prepaid Taxes
PrepaidTaxes
781000 usd
CY2022Q3 us-gaap Prepaid Insurance
PrepaidInsurance
1103000 usd
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
275000 usd
CY2022Q3 us-gaap Deposits Assets Current
DepositsAssetsCurrent
101000 usd
CY2021Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
131000 usd
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
326000 usd
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
498000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1537000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1685000 usd
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
356000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2023000 usd
CY2022Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
2072000 usd
CY2021Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
0 usd
CY2022Q3 angn Accrued Direct Research Costs Current
AccruedDirectResearchCostsCurrent
1999000 usd
CY2021Q4 angn Accrued Direct Research Costs Current
AccruedDirectResearchCostsCurrent
764000 usd
CY2022Q3 angn Accrued Operating Liabilities Current
AccruedOperatingLiabilitiesCurrent
481000 usd
CY2021Q4 angn Accrued Operating Liabilities Current
AccruedOperatingLiabilitiesCurrent
432000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4908000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3219000 usd
angn Number Of Votes Per Share Of Common Stock
NumberOfVotesPerShareOfCommonStock
1 vote
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4230162 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.92
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2257100 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.93
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
914621 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
9.37
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5572641 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.48
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3862362 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.34
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y1M6D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.74
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.13
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.18
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.97
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2200000 usd
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1148123 shares
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
-763000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2184000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
667000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10019000 usd
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1148123 shares
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
301000 usd
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
325000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
1015000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
914000 usd
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
108000 usd
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
67000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
252000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
282000 usd
CY2022Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
6000 usd
CY2021Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
16000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
18000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
58000 usd
us-gaap Lease Cost
LeaseCost
1285000 usd
CY2022Q3 us-gaap Lease Cost
LeaseCost
415000 usd
CY2021Q3 us-gaap Lease Cost
LeaseCost
408000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1305000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1209000 usd
us-gaap Lease Cost
LeaseCost
1254000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
966000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
861000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
624000 usd
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M18D
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.095
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.101
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
322000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1104000 usd
CY2022Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
94000 usd
CY2022Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
94000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
516000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4456000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
750000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3706000 usd
CY2021Q4 us-gaap Lessee Finance Lease Term Of Contract1
LesseeFinanceLeaseTermOfContract1
P42M
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
28000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
43000 usd
CY2022Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y7M6D
CY2022Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.011
CY2022Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
25000 usd
CY2022Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
31000 usd
CY2022Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
244000 usd
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022Q3 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0 usd
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.08
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8988000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-15704000 usd
us-gaap Net Income Loss
NetIncomeLoss
-32367000 usd
us-gaap Net Income Loss
NetIncomeLoss
-69463000 usd
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30113407 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30113407 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29829577 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29829577 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30016079 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30016079 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27671310 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27671310 shares
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.51
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6737174 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5589138 shares
CY2022Q1 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
1100000 usd
CY2022Q1 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
500000 usd
CY2022Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0 usd

Files In Submission

Name View Source Status
0001601485-22-000070-index-headers.html Edgar Link pending
0001601485-22-000070-index.html Edgar Link pending
0001601485-22-000070.txt Edgar Link pending
0001601485-22-000070-xbrl.zip Edgar Link pending
angn-20220930.htm Edgar Link pending
angn-20220930.xsd Edgar Link pending
ex311_angnx09302022-10xq.htm Edgar Link pending
ex312_angnx09302022-10xq.htm Edgar Link pending
ex321angn-09302022x10xq.htm Edgar Link pending
ex322_angnx09302022-10xq.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
angn-20220930_lab.xml Edgar Link unprocessable
angn-20220930_pre.xml Edgar Link unprocessable
angn-20220930_htm.xml Edgar Link completed
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
separationpacket-jn81522.htm Edgar Link pending
separationpacket-jn81522001.jpg Edgar Link pending
separationpacket-jn81522002.jpg Edgar Link pending
separationpacket-jn81522003.jpg Edgar Link pending
separationpacket-jn81522004.jpg Edgar Link pending
separationpacket-jn81522005.jpg Edgar Link pending
separationpacket-jn81522006.jpg Edgar Link pending
separationpacket-jn81522007.jpg Edgar Link pending
separationpacket-jn81522008.jpg Edgar Link pending
separationpacket-jn81522009.jpg Edgar Link pending
separationpacket-jn81522010.jpg Edgar Link pending
separationpacket-jn81522011.jpg Edgar Link pending
separationpacket-jn81522012.jpg Edgar Link pending
separationpacket-jn81522013.jpg Edgar Link pending
separationpacket-jn81522014.jpg Edgar Link pending
separationpacket-jn81522015.jpg Edgar Link pending
separationpacket-jn81522016.jpg Edgar Link pending
separationpacket-jn81522017.jpg Edgar Link pending
separationpacket-jn81522018.jpg Edgar Link pending
separationpacket-jn81522019.jpg Edgar Link pending
Show.js Edgar Link pending
angn-20220930_def.xml Edgar Link unprocessable
angn-20220930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable